

DAFTAR PUSTAKA

1. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology 2017. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* 2017; 00: 1–66.
2. Marc P, Bonaca, Sabatine MS. Approach to the patient with chest Pain In: Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Tenth Edition. Saunders Elsevier. 2015; 1059-66.
3. Bodor GS. Biochemical markers of myocardial damage. *eJIFCC.* 2016; 95-111.
4. Navarro CO, Kurth MJ, Lamont JV, Menown IB, Ruddock MW, Fitzgerald SP, et al. Diagnostic performance of a combination biomarker algorithm for rule-out of acute myocardial infarction at time of presentation to the emergency department, using heart-type fatty acid binding protein and high sensitivity troponin T test. *J Clin Exp Cardiol.* 2018; 9(8): 1-9.
5. Anvari MS, Karimi M, Shafiee A, Boroumand M, Bozorgi A, Sedaghat R, et al. Complementary diagnostic value of heart type fatty acid-binding protein in early detection of acute myocardial infarction. *Crit Pathways in Cardiol* 2018;17: 43–46.
6. Pyati AK, Devaranavadagi BB, Sajjannar SL, Nikam SV, Shannawaz M, Patil S. Heart-type fatty acid-binding protein, in early detection of acute myocardial infarction: comparison with ck-mb, troponin i and myoglobin. *Ind J Clin Biochem.* 2016; 439–445. .
7. Willemsen RTA, Dinant GJ, Glatz JFC. Biomarkers of myocardial cell damage: heart-type fatty acid binding protein (H-FABP) for the early evaluation of suspected acute coronary syndrome. In: Patel VB, Preedy VR, editors. *Biomarkers in cardiovascular disease.* Springer Reference. 2016; 235-65.
8. Rashid S, Malik A, Khurshid R, Faryal U, Qazi S. The diagnostic value of biochemical cardiac markers in acute myocardial infarction. *Intech Open.* 2018; 23-39.
9. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* 2011; (32): 2999–3054.
10. Lippi G, Mattiuzzi C, Cervellin G. Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction. *Clin Biochem.* 2013; 46: 26–30.
11. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. *Eur Heart J.* 2018; 00: 1-13.
12. Katus H, Searle J, Giannitsis E. How to use high-sensitivity cardiac troponin in acute cardiac care. *Hindawi Publishing Corporation.* 2013; 1-4.

13. Sabatine MS, Cannon CP. Approach to the patient with chest pain In: Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Tenth Edition. Saunders Elsevier. 2015;1057-67.
14. Kabekkodu SP, Mananje SR, Saya RP. A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. JCDR. 2016;10(1): 7-10.
15. Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomedical Reports. 2015; 743-8.
16. Rako I. Do we need additional laboratory markers of ACS? Signa Vitae. 2016; 11: 73-5.
17. Body R, Carley S, Burrows G, Pemberton P, Mackway-Jones J K. Combining heart fatty acid binding protein and high sensitivity troponin in the emergency department. Scientific Abstracts 14th International Conference on Emergency Medicine. 2012; 39-40.
18. Vupputuri A, Shekar S, Krishnan S, Venugopal K, Natarajan KU. Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain. Ind Heart J. 2015;67:538-542.
19. Agnello L, Bivona G, Novo G, Scazzone C, Muratore R, Levantino P, et al. Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study. Scand J Clin Lab Investig. 2017; 1-5
20. Kennedy J, Lasserson D, den Bruel AV, Price CP, Thompson M, Heneghan C, et al. Point-of-care testing for heart-type Fatty Acid Binding Protein: Horizon Scan Report 0039. National Institute for Health Research. 2014.
21. Cannon CP, Braunwald E. Non ST segment elevation acute coronary syndrome, in: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles of internal medicine 19th Ed. McGraw-Hill. 2015: 1599-1611.
22. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics 2021 update: a report from the American Heart Association. Circulation. 2021
23. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJL, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010. Circulation. 2014;129:1483-92.
24. Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi Kesehatan Jantung. Pusdatin Kementerian Kesehatan RI. 2014.
25. Wilder J, Sabatine MS, Lilly LS. Acute coronary syndromes, in: Lilly LS, Pathophysiology of heart disease. Wolters Kluwer. 2016; 162-91.
26. Trisnohadi HB, Muhadi. Angina pectoris tak stabil/ infark miokard akut tanpa elevasi ST, dalam: Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI. Interna Publishing. 2015; 1449-56.
27. Kim MC, Kini AS, Fuster V. Definition and pathogenesis of acute coronary syndromes, in: Hurst's The Heart Manual of Cardiology, Thirteenth Edition. McGraw-Hill. 2013; 249-257.
28. Scirica BM, Morrow DA. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features, in: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition. Saunders Elsevier. 2015; 1068-94.

29. Buja LM. The pathobiology of acute coronary syndromes. *Tex Heart Inst J*. 2013; 40(3): 221-8.
30. Canty JMJr, Duncker DJ. Coronary blood flow and myocardial ischemia. In: Mann DL, Zipes DP, Libby P, Bonow RO. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*, Tenth Edition. Saunders Elsevier. 2015; 1029-55.
31. Frangogiannis NG. Pathophysiology of myocardial infarction. *Comr Physiol*. 2015; 5: 1841-75.
32. Mair J. Tissue release of cardiac markers: from physiology to clinical applications. *Clin Chem Lab Med*. 1999; 37: 1077-84.
33. Mirvis DM, Goldberger AL. Electrocardiography, in: Mann DL et al. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*, Tenth Edition. Saunders Elsevier. 2015; 117-157.
34. Irmalita, Juzar DA, Andrianto, Setianto BY, Tobing DPL, Firman D, dkk. *Pedoman tatalaksana sindrom koroner akut*. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2015.
35. Makmun LH, Alwi I, Ranty R. *Pedoman tatalaksana sindrom koroner akut dengan elevasi segmen ST*. Pusat Penerbit Ilmu Penyakit Dalam. 2009: 1-56.
36. Alwi I. Infark miokard akut dengan elevasi ST, dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata MK, Setiyohadi B, Syam AF. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Interna Publishing. 2015; hlm1457-74.
37. Anderson JL, Morrow DA. Acute myocardial infarction. *N Engl J Med* 2017; 376: 2053-2064.
38. Dekker MS, Mosterd A, van't Hof AWJ, Hoes AW. Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. *Heart*. 2010; 96:1001-1010.
39. Gilardi E, Iacomini P, Marsiliani D, Marco GD, Covino M. Biomarkers in the prediction and management of acute coronary syndromes: current perspectives. *Res Rep Clin Cardiol*. 2014; 21–31.
40. Ye XD, He Y, Wang S, Wong GT, Irwin MG, Xia Z. Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. *Acta Pharmacol Sin*. 2018: 1–9.
41. Glatz JFC. Added value of H-FABP as a plasma biomarker for the early evaluation of suspected acute coronary syndrome. *Clin. Lipidol*. 2014; 9(2): 205-18.
42. Aldous SJ. Cardiac biomarkers in acute myocardial infarction. *International Journal of Cardiology*. 2013; (164): 282–294.
43. Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponin: from myocardial infarction to chronic disease. *Cardiovasc Res*. 2017; 113: 1708-18.
44. Otaki Y, Watanabe T, Takahashi H, Hirayama A, Narumi T, Kadowaki S, et al. Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: The Takahata Study. *PLoS ONE*. 2014; 9 (5): e94834.
45. Kakoti A, Goswami P. Heart type fatty acid binding protein: Structure, function and biosensing applications for early detection of myocardial infarction. *Biosens and Bioelectron*. 2013; 400–411.

46. Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: a systemic review. *Clin Chim Acta*. 2017; 44–53.
47. Alhadi HA, Fox KAA. Do we need additional markers of myocyte necrosis: the potential value of heart-type fatty acid binding protein. *Q J Med*. 2004; 97: 187-98.
48. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. *Nat Rev Drug Discov*. 2008; 7: 489-503.
49. Hoffmann U, Espeter F, Wei C, Nejad PA, Lang S, Brueckmann M, et al. Ischemic biomarker heart-type fatty acid binding protein (HFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. *BMC Cardiovascular Disorders*. 2015; 15:50.
50. El Missiri A, Okasha N, Badr T. Heart-type fatty acid-binding protein detects more patients with non-ST segment elevation myocardial infarction compared to troponin-T. *Egypt Heart J*. 2016; 68, 11–16.
51. Dupuy AM, Cristol JP, Kuster N, Reynier R, Lefebvre S, Badiou S, et al. Performances of the heart fatty acid protein assay for the rapid diagnosis of acute myocardial infarction in ED patients. *Am. J. Emerg. Med*. 2015; 326–330.
52. Willemsen RTA, van Severen E, Vandervoort PM, Grieten L, Buntinx F, Glatz JFC, et al. Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: Optimal cut-off point, diagnostic value and future opportunities in primary care. *Eur J Gen Pract*. 2015; 21: 156-163.
53. Young JM, Pickering JW, George PM, Aldous SJ, Wallace J, Frampton CM, et al. Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. *BMC Emergency Medicine*. 2016; 16-34.
54. Chandra S, Kulshrestha MR, Raj A, Tiwari BC. The utility of heart type fatty acid binding protein in acute myocardial infarction patients. *Saudi J Pathol Microbiol*. 2020; 5(2): 115-120.
55. Reddy LL, Shah SAV, Dherai AJ, Ponde CK, Ashavaid TF. Troponin T and Heart Type Fatty Acid Binding Protein (h-Fabp) as Biomarkers in Patients Presenting with Chest Pain. *Ind J Clin Biochem*. 2016; 31(1):87–92.
56. Puspitawati I, Sudana ING, Setyawati, Sukorini U. Heart fatty acid binding protein sebagai petanda biologis diagnosis sindrom koroner akut. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2016; 22 (2): 127–32.
57. Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, Hall AS. EMMACE-2 Investigators. *J. Am. Coll. Cardiol*. 2007;50(21):2061-7.
58. Nursalim A, Suryaatmadja M, Panggabean M. Potential clinical application of novel cardiac biomarkers for acute myocardial infarction. *Acta Med Indones-Indones J Intern Med*. 2013; 45(3): 240-50.
59. Kellens S, Verbrugge FH, Vanmechelen M, Grieten L, Van Lierde J, Dens J, et al. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. *Eur Heart J: Acute Cardiovascular Care*. 2015; 1-6

60. Pedersen LR, Frestad D, Michelsen MM, Mygind ND, Rasmussen H, Suhrs HE, et al. Risk factors for myocardial infarction in women and men: a review of the current literature. *Curr Pharm Des.* 2016; 22(26): 3835 - 52.
61. Atay E, Guzel M, Amanvermez R, Demir MT, Erenler AK, Ozgen E, et al. Role of Gal-3 and H-FABP in the early diagnosis of acute coronary syndrome. *Bratisl Med J* 2019; 120(2):124-30.
62. Shahawy S, Libby P. Atherosclerosis, in: Lilly LS (ed). *Pathophysiology of heart disease*, sixth edition. Wolters Kluwer. 2016; 112-33.
63. Jacobs LHJ, vanBorren M, Gemen E, vanEck M, van Son B, Glatz JFC. et al. Rapidly rule out myocardial infarction by combining copeptin and heart-type fatty acid binding protein with cardiac troponin. *Ann Clin Biochem.* 2015; 52 (5): 550-61.
64. Eissa M, Hussein E, Saad Z, Elrawy M. Heart-type fatty acid binding protein (H-FABP) is a more accurate biomarker for early diagnosis of patients with acute coronary syndrome. *Int.J.Adv.Res.* 2017; 5(4):1832-46.
65. Antman EM, Loscalzo J. Ischemic heart disease, in: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. *Harrison's Principles of internal medicine* 19th Ed. McGraw-Hill. 2015: 1578-93.
66. Elkhader BA, Abdulla AA, Omer MAA. Correlation of smoking and myocardial infarction among sudanese male patients above 40 years of age. *Pol J Radiol.* 2016; 81: 138-140.
67. Roy A, Rawal I, Jabbour S, Prabhakaran D. Tobacco and cardiovascular disease: a summary of evidence, in: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R. *Cardiovascular, Respiratory, and Related Disorders.* The World Bank Group. 2017: 57-122.
68. Carrick D, Haig C, Maznyczka AM, Carberry J, Mangion K, Ahmed N, et al. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. *Hypertension.* 2018; 72(3):720-30 .
69. Picariello C, Lazzeri C, Attan`a P, Chiostrri M, Gensini GF, Valente S. The impact of hypertension on patients with acute coronary syndromes. *Int J Hypertens.* 2011; 1-7.
70. Pedrinelli R, Ballo P, Fiorentini C, Denti S, Galderisi M, Ganau A. Hypertension and acute myocardial infarction: an overview. *Italian Federation of Cardiology.* 2012; 13(3): 194-202.
71. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovasc Diabetol.* 2018; 17:83.
72. Cercato C, Fonseca FA. Cardiovascular risk and obesity. *Diabetol Metab Syndr.* 2019; 11:7.
73. Wentworth JM, Furlanos S, Colman PG. Body mass index correlates with ischemic heart disease and albuminuria in long standing type 2 diabetes. *Diab Res Clin Pract.* 2012; 97:57–62.

74. Orak M, Ustundag M, Guloglu C, Ozhasenekler A, Alyan O, Kale E. The role of heart-type fatty acid binding protein in the early diagnosis of acute coronary syndrome and its comparison with troponin I and creatinine kinase-MB isoform. *American Journal of Emergency Medicine*. 2010; 28: 891-6.
75. Glatz JFC, Mohren R. Plasma reference value of heart-type fatty acid-binding protein, the earliest available plasma biomarker of acute myocardial infarction. *Health*. 2013; 5: 1206-9.
76. Dahlan MS. *Penelitian diagnostik*. Penerbit Salemba Medika. 2009.
77. Pusponegoro HD, Wirya W IGN, Pudjiadi AH, Bisanto F, Zulkarnain SZ. Uji diagnostik, dalam: Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis*. Sagung Seto. 2011; 219-244.
78. Freund Y, Chenevier-Gobeaux C, Leumani F, Claessens YE, Allo JC, Doumenc B, et al. Heart-type fatty acid binding protein and the diagnosis of acute coronary syndrome in the ED. *American Journal of Emergency Medicine*. 2012; 30: 1378-84.
79. Hussein BJ, Saleh BO, Abbas NN, Ahmeid MS. Role of serum fatty acid binding protein and high sensitivity cardiac troponin in diagnosis and differentiation of acute coronary syndrome. *The Medical Journal of Tikrit University*. 2019; 25(2): 11-18.
80. Carroll C, Al Khalaf M, Stevens JW, Leaviss J, Goodacre S, Collinson PO, et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systemic review and meta-analysis. *Emerg Med J*. 2012; 1-7.
81. Goel H, Melot J, Krinock MD, Kumar A, Nadar SK, Lip GYH. Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. *Annals of Medicine*. 2020; 52(8): 444-61.

